GlassScriptPhysician profile
Toni Cottongim
NPI 1710924139
$526.41
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $124.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $129.24 | 2019-2020 | |
| Amgen INC. | $81.44 | 2019-2020 | |
| Pfizer INC. | $62.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $53.42 | 2019-2020 | |
| Lilly USA, LLC | $35.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.27 | 2019 | |
| Cranial Technologies, INC | $17.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.92 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.14 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.65 | 2019 | |
| Sanofi Pasteur INC. | $13.05 | 2019 | |
| Merck Sharp & Dohme LLC | $11.75 | 2019 | |
| Shire North American Group INC | $10.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Cottongim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.